Literature DB >> 17003944

Measles and rubella antibody status in children after treatment for acute lymphoblastic leukemia.

Sáhlua M Volc1, Maria T A Almeida, Márcia D Abadi, Ana Lucia Cornacchioni, Vicente Odone Filho, Lílian M Cristofani.   

Abstract

OBJECTIVE: To assess the vaccination history and the status of vaccine-induced protection from measles and rubella in children after treatment for acute lymphoblastic leukemia.
METHODS: Measles and rubella immunological status was assessed by the ELISA technique for 22 children previously treated for acute lymphoblastic leukemia.
RESULTS: From the total of 22 patients, 20 had been given two doses of measles vaccine and 18 had had one dose of rubella vaccine. The percentage of patients seropositive for measles and rubella were 65 and 88.9%, respectively, with no correlation with age of patient, aggression of treatment or the time passed between the end of treatment and sample collection.
CONCLUSIONS: We detected that vaccination had failed against measles and rubella in 35 and 11.1% of cases, respectively. We recommend that a measles booster be given after the completion of treatment for acute lymphoblastic leukemia and that rubella immunity status should be assessed at this point, with revaccination performed when necessary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003944     DOI: 10.2223/JPED.1532

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  3 in total

1.  Antibody responses to Hepatitis B and measles-mumps-rubella vaccines in children who received chemotherapy for acute lymphoblastic leukemia.

Authors:  Simone Santana Viana; Gustavo Santos Araujo; Gustavo Baptista de Almeida Faro; Lana Luíza da Cruz-Silva; Carlos André Araújo-Melo; Rosana Cipolotti
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 2.  Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Authors:  C T Rieger; B Liss; S Mellinghoff; D Buchheidt; O A Cornely; G Egerer; W J Heinz; M Hentrich; G Maschmeyer; K Mayer; M Sandherr; G Silling; A Ullmann; M J G T Vehreschild; M von Lilienfeld-Toal; H H Wolf; N Lehners
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

Review 3.  Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review.

Authors:  Shannon E MacDonald; Airlie Palichuk; Linda Slater; Hailey Tripp; Laura Reifferscheid; Catherine Burton
Journal:  Hum Vaccin Immunother       Date:  2021-07-16       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.